Cramer's 'Mad Money' Recap: Biotech Buys

However, he advised market players to do their own handholding -- called homework -- and get into the stock ahead of the pack.

Mispriced Merger

Another stock that Cramer believes people should get into ahead of the conference is Thermo Fisher Scientific (TMO Quote). He suggested people buy it at 10 a.m. EDT Tuesday, before the company is scheduled to present at the conference at 11 a.m.

On Nov. 9, TMO merged with Fisher Scientific and made itself into a better market-cap company, Cramer said. This merger, along with TMO's "coming out party" on Tuesday, should do good things for the stock, he said.

TMO is a "premier arms supplier to the whole pharmaceutical business," and while it may not be a pure play, all of its end markets are "strong," Cramer said. In addition, "ever since the merger, analysts have been falling over themselves" to raise its estimates.

However, Cramer believes the analysts and the Street are still underestimating "what a powerhouse it has become." TMO, which should be able to cut costs, increase margins and have 32% growth this year with the merger, is "mispriced," he said.

"It's the biggest, the best and deserves to trade at a premium to other life sciences companies," Cramer said. Meanwhile, it is currently priced below its lower, not-best-of-breed competitors.